News | January 31, 2014

PICSO Impulse System Four Month Follow-Up Shows Infarct Size-Reduction

Miracor Medical PICSO Impulse System Clinical Trial Cath Lab

Coronary sinus pressure increase during two cycles of PICSO (clinical data from the Prepare PICSO study).

January 31, 2014 — Miracor Medical Systems completed four months’ follow-up of patients enrolled in the “Prepare RAMSES” clinical trial of PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) System. PICSO is designed to improve myocardial perfusion following primary PCI (Percutaneous Coronary Intervention, or angioplasty). Interim data from early results indicate a strong trend towards a larger reduction in infarct for patients receiving the PICSO therapy in complement with primary PCI. A total of 30 patients have successfully enrolled in the clinical trial, with no device-related adverse events. 
 
The study is underway in several European centers with Principal Investigator Jan J. Piek, M.D., Ph.D., professor of interventional cardiology and director of the Heart Centre, Academic Medical Centre, University of Amsterdam. Miracor Medical is expanding PICSO’s CE marking throughout Europe. 
 
The Miracor PICSO Impulse System is designed to treat acute heart attack STEMI (ST-segment elevation myocardial infarction) patients in complement to coronary angioplasty. 
 
For more information: www.miracormedical.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Overlay Init